"The findings, published in The New England Journal of Medicine and presented at the European Society of Cardiology Congress, come from the REBOOT trial, which followed 8,505 patients across Spain and Italy. Researchers found that beta blockers, long considered a cornerstone of post-heart attack care, failed to improve survival rates, prevent repeat heart attacks, or reduce hospitalizations for heart failure."
"Even worse, a substudy revealed that women with normal heart function who took beta blockers had a 2.7% higher absolute risk of death compared to those who didn't. Meanwhile, men experienced no such risk. So why are these drugs still being prescribed to more than 80% of heart attack patients worldwide? A medical paradigm shattered The REBOOT trial, led by Dr. Valentin Fuster of Mount Sinai Fuster Heart Hospital and Dr. Borja Ibáñez of Spain's National Center for Cardiovascular Investigation, challenges decades of medical dogma."
The REBOOT trial followed 8,505 heart attack patients across Spain and Italy. Beta blockers did not improve survival, prevent repeat myocardial infarction, or reduce hospitalizations for heart failure. A substudy showed women with normal left ventricular function who used beta blockers had a 2.7% higher absolute risk of death compared with non-users, while men showed no increased risk. Modern acute and secondary cardiac treatments have reduced the incremental benefit of beta blockers. Despite the lack of demonstrated benefit for most patients, more than 80% of heart attack survivors continue to receive beta blockers, prompting calls to update clinical guidelines.
Read at Natural Health News
Unable to calculate read time
Collection
[
|
...
]